Taiwanese Journal of Obstetrics and Gynecology
Volume 48, Issue 3 , Pages 245-248, September 2009

Beneficial Effect of Luteal-phase Gonadotropin-releasing Hormone Agonist Administration on Implantation Rate Afterintracytoplasmic Sperm Injection

Research and Clinical Center for Infertility, Shahid Sadoughi University of Medical Sciences, Yazd, Iran

Accepted 3 July 2008.

Article Outline

Summary 

Objective

To evaluate the effect of gonadotropin-releasing hormone (GnRH) agonist, administered in the luteal phase, on intracytoplasmic sperm injection (ICSI) outcome.

Materials and Methods

One hundred and eighty women undergoing ovarian stimulation for ICSI were enrolled in this study. Patients were randomly assigned to receive a single dose of GnRH agonist or placebo. Implantation rate and clinical pregnancy rate were the main outcomes.

Results

Administration of 0.1 mg of the GnRH agonist triptorelin on day 3 after embryo transfer led to a significant improvement in implantation rate (12.3% vs. 7.3%) and clinical pregnancy rate (25.5% vs. 10.0%) as compared with placebo.

Conclusion

Luteal phase GnRH agonist administration enhances ICSI clinical outcomes.

Key Words:  embryo implantation , GnRH agonist , intracytoplasmic sperm injection , luteal phase support

No full text is available. To read the body of this article, please view the PDF online.

 

Back to Article Outline

References 

  1. Macklon NS , Fauser BC . Impact of ovarian hyperstimulation on the luteal phase . J Reprod Fertil Suppl . 2000;55:101–108
  2. Pritts EA , Atwood AK . Luteal phase support in infertility treatment: a meta-analysis of the randomized trials . Hum Reprod . 2002;17:2287–2299
  3. Smitz J , Camus M , Devroey P , Bollen N , Tournaye H , Van Steirteghem AC . The influence of inadvertent intranasal buserelin administration in early pregnancy . Hum Reprod . 1991;6:290–293
  4. Al Inizi ST , Asaad M , Schick J . Luteal phase support in in-vitro fertilization . Middle East Fertil Soc J . 2006;11:64–69
  5. Tesarik J , Hazout A , Mendoza C . Enhancement of embryo developmental potential by a single administration of GnRH agonist at the time of implantation . Hum Reprod . 2004;19:1176–1180
  6. Pirard C , Donnez J , Loumaye E . GnRH agonist as novel luteal support: results of a randomized, parallel group, feasibility study using intranasal administration of buserelin . Hum Reprod . 2005;20:1798–1804
  7. Pirard C , Donnez J , Loumaye E . GnRH agonist as luteal phase support in assisted reproduction technique cycles: results of a pilot study . Hum Reprod . 2006;21:1894–1900
  8. Tesarik J , Hazout A , Mendoza-Tesarik R , Mendoza N , Mendoza C . Beneficial effect of luteal-phase GnRH agonist administration on embryo implantation after ICSI in both GnRH agonist-and antagonist-treated ovarian stimulation cycles . Hum Reprod . 2006;21:2572–2579
  9. Tavaniotou A , Albano C , Smitz J , Devroey P . Impact of ovarian stimulation on corpus luteum function and embryonic implantation . J Reprod Immunol . 2002;55:123–130
  10. Iwashita M , Kudo Y , Shinozaki Y , Takeda Y . Gonadotropin-releasing hormone increases serum human chorionic gonadotropin in pregnant women . Endocr J . 1993;40:539–544
  11. Lin LS , Roberts VJ , Yen SS . Expression of human gonadotropin-releasing hormone receptor gene in the placenta and its functional relationship to human chorionic gonadotropin secretion . J Clin Endocrinol Metab . 1995;80:580–585
  12. Kitajima Y , Endo T , Manase K , Nishikawa A , Shibuya M , Kudo R . Gonadotropin-releasing hormone agonist administration reduced vascular endothelial growth factor (VEGF), VEGF receptors, and vascular permeability of the ovaries of hyperstimulated rats . Fertil Steril . 2004;81(Suppl 1):842–849

PII: S1028-4559(09)60297-7

doi:10.1016/S1028-4559(09)60297-7

Taiwanese Journal of Obstetrics and Gynecology
Volume 48, Issue 3 , Pages 245-248, September 2009

Article Tools